Fed Governor Adriana Kugler to resign
On Thursday, TD Cowen reaffirmed its Buy rating and $22.50 price target for Alphatec Holdings (NASDAQ:ATEC), a medical technology company. The endorsement comes after Alphatec reported solid fourth-quarter results for 2024, which aligned with its previous announcements. According to InvestingPro data, the stock has seen a remarkable 75% surge over the past six months, though analysis suggests the shares are currently trading above their Fair Value. The company’s performance was notable for meeting its projected targets, and it has issued guidance for 2025 that suggests a continuation of this trend.
The guidance for the upcoming year includes an expectation of 20% growth, a forecast that appears feasible given Alphatec’s impressive 27.2% revenue growth in the last twelve months. The company maintains strong liquidity with a current ratio of 2.32, indicating robust working capital management. This growth trajectory is particularly significant in light of recent disruptions within the spine market, which Alphatec seems poised to capitalize on. The company’s strategic moves within this sector are expected to further solidify its market position.
TD Cowen’s analyst highlighted Alphatec’s adept cash management strategies, which are set to yield positive cash flow throughout 2025. This financial outlook is anticipated to resonate well with the investment community, as positive cash flow is often a key indicator of a company’s financial health and operational efficiency. For deeper insights into Alphatec’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
Alphatec’s commitment to growth and positive cash flow is underscored by its ability to navigate market challenges and leverage opportunities within the medical technology industry. The company’s focus on the spine market, coupled with effective financial stewardship, has positioned it as a top pick among small to mid-cap (SMIDCap) companies in the eyes of TD Cowen.
Investors will likely monitor Alphatec’s progress closely, as its strategies and market dynamics unfold over the coming year. The company’s adherence to its guidance and financial projections will be crucial in maintaining investor confidence and justifying the continued endorsement from analysts like those at TD Cowen.
In other recent news, Alphatec Holdings Inc. reported its Q4 2024 earnings, revealing an earnings per share (EPS) of -$0.23, which missed the analysts’ forecast of -$0.05. Despite this, the company’s revenue for the quarter reached $177 million, surpassing expectations of $170.35 million. Alphatec’s revenue grew by 28% year-over-year, marking a significant achievement in their financial performance. The company also achieved its first quarter of positive cash flow since its transformation, generating $9 million in free cash flow. For 2025, Alphatec projects revenue of $732 million, indicating a 20% growth from 2024. The company anticipates a positive cash flow and an adjusted EBITDA of $75 million. Furthermore, Alphatec is planning key product launches, including navigation robotics, in the latter half of 2025, which could further bolster growth. Analyst firms have yet to publicly comment on any stock upgrades or downgrades following these announcements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.